Allergan And MAP Team Up On Inhalable Migraine Treatment
This article was originally published in The Pink Sheet Daily
Executive SummaryDeal with Allergan focuses on detailing to neurologists and pain specialists, leaving MAP free to do other co-promotion deals.
You may also be interested in...
FDA again cites inspection issues related to a third-party facility where the product canister for the migraine drug is manufactured, as well as the manufacturing process itself; Allergan says it recently completed an acquisition of that third-party firm, thereby bringing the inhaled treatment’s manufacturing in-house.
Allergan/MAP Planned Merger, Approval Of NuPathe’s Triptan Patch Change U.S. Landscape For Migraine Therapy
While Allergan plans to diversify its portfolio in migraine by acquiring partner MAP and its candidate for acute migraine, NuPathe seeks a partner for a triptan patch product expected to avoid the nausea suffered by many migraine patients.
Allergan’s buyout of MAP Pharma is an unusual case of a deal centered on drug under the shadow of a “complete response” letter, but it’s not the only one. How does it compare to recent precedents.